Rapid Clinical Updates: Antibiotic Stewardship in Pneumonia-Slides

Pdf Summary

This educational session on antibiotic stewardship in pneumonia features experts Drs. Moira McNulty, Paul Caseley, and moderator Joseph Sweigart, providing rapid clinical updates with emphasis on community-acquired pneumonia (CAP).<br /><br />Key points include updated definitions: CAP occurs outside healthcare settings; hospital-acquired pneumonia (HAP) arises 48+ hours after admission; ventilator-associated pneumonia (VAP) affects ventilated patients 48+ hours. The HCAP category was eliminated to reduce unnecessary broad-spectrum antibiotic use.<br /><br />CAP accounts for substantial morbidity and mortality; up to 10% require hospitalization. Diagnosis of CAP is often overused, with 10-30% lacking confirmatory clinical and radiographic evidence. Differentiation between uncomplicated vs. complicated and severe vs. non-severe CAP guides testing and treatment. Complicated CAP involves local/systemic issues like empyema or septic shock. Immunocompromised patients require special consideration and often longer therapy.<br /><br />Initial antibiotic therapy for non-severe CAP typically includes a beta-lactam plus macrolide or fluoroquinolone monotherapy, without need for routine blood cultures or urinary antigen tests unless severe. Ancillary testing is reserved for severe cases or treatment failure. Empiric anti-MRSA or antipseudomonal coverage is indicated only with specific risk factors (prior isolates, recent IV antibiotics, local epidemiology). A negative MRSA nasal swab allows safe discontinuation of anti-MRSA agents.<br /><br />Updated evidence supports shorter antibiotic durations: 3 days for stable outpatients, 3-5 days inpatient depending on clinical stability (absence of fever, stable vitals). Longer courses (7+ days) remain for severe CAP or confirmed Staphylococcus aureus/pseudomonas infections. Corticosteroids are not recommended for non-severe CAP but may benefit severe CAP except in influenza infection.<br /><br />Prevention strategies include vaccination (pneumococcal, influenza, RSV, COVID-19), smoking cessation, and oral hygiene. For HAP/VAP, combination gram-negative coverage and routine anaerobic coverage are discouraged; 7-day antibiotic courses are typical, with shorter courses possible in select VAP.<br /><br />Stewardship benefits reported include improved outcomes, reduced length of stay, decreased Clostridioides difficile infection, reduced antibiotic resistance, less kidney injury, and lower costs.<br /><br />In summary, evidence-based stewardship in pneumonia emphasizes accurate diagnosis, targeted empiric therapy with appropriate narrow-spectrum antibiotics, minimal ancillary testing unless indicated, and shorter treatment durations guided by clinical stability to optimize patient outcomes and minimize adverse effects.

Meta Tag

Concept Community-Acquired Pneumonia

Concept Empiric Antibiotic Therapy

Concept Hospital-Acquired Pneumonia

Concept Ventilator-Associated Pneumonia

Concept Disease Severity

Keywords

antibiotic stewardship

community-acquired pneumonia

hospital-acquired pneumonia

ventilator-associated pneumonia

beta-lactam therapy

macrolide antibiotics

fluoroquinolone monotherapy

MRSA nasal swab

short-course antibiotic therapy

pneumococcal vaccination

Community-Acquired Pneumonia

Empiric Antibiotic Therapy

Hospital-Acquired Pneumonia

Ventilator-Associated Pneumonia

Disease Severity